<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02006979</url>
  </required_header>
  <id_info>
    <org_study_id>H13-03090</org_study_id>
    <nct_id>NCT02006979</nct_id>
  </id_info>
  <brief_title>Acute Exercise Cardioprotection From Doxorubicin</brief_title>
  <official_title>The Effects of Exercise Before Doxorubicin Chemotherapy on Cardiac Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>British Columbia Cancer Agency</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In rodents, a single bout of exercise prior to injection of a chemotherapy agent used to
      treat breast cancer prevents or attenuates a number of markers of cardiac injury. This study
      will investigate whether this finding translates to human breast cancer patients.
      Participants scheduled to receive chemotherapy for breast cancer will be randomized to
      exercise or no exercise 24 hours prior to every chemotherapy treatment. The effect on cardiac
      function will be compared between groups noninvasively by echocardiography and
      electrocardiography and a venous blood draw at baseline before chemotherapy, after the first
      treatment and at the end of chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Purpose The purpose of this study is to investigate whether performing a single bout of
           exercise 24 hours prior to receiving infusions of the anthracycline chemotherapy agent
           doxorubicin for breast cancer can prevent some of the damaging cardiac effects.
           Currently, doxorubicin is the most effective chemotherapy agent for breast cancer but is
           also the most damaging. As such, increased risk of cardiovascular disease is a growing
           concern in doxorubicin-treated patients. Current strategies for minimizing cardiac
           injury are dose reduction and discontinuation of therapy, which compromise the
           effectiveness of the treatment. Interventions that can minimize the cardiac injury
           associated with doxorubicin could reduce cancer-related and cardiovascular
           disease-related mortality in women diagnosed with breast cancer.

        2. Hypotheses 1. Performing an acute bout of exercise within 24 hours before anthracycline
           infusion will decrease the acute negative change in subclinical markers of
           cardiotoxicity after the first anthracycline infusion seen in those who do not exercise
           for 72 hours prior.

      2. Performing exercise within 24 hours before every infusion of anthracycline will decrease
      the negative change in markers of cardiac dysfunction seen at the end of chemotherapy in
      those who do not exercise for 72 hours prior to each infusion.

      3) Justification An acute exercise bout prior to induction of a myocardial infarction in
      animals provides cardioprotective benefit by reducing the size of the infarct relative to
      control animals. Recently, acute exercise performed 24 hours before anthracycline injection
      in rodents has also provided a cardioprotective benefit. Oxidative stress and apoptosis of
      cardiomyocyte mitochondria are primary mechanisms of anthracycline-induced cardiotoxicity.
      The single acute bout of exercise prevented or attenuated some of the anthracycline-induced
      negative effects on cardiomyocytes including oxidative stress, apoptosis, mitochondrial
      dysfunction, as well as systolic dysfunction. There are no studies to date that have
      investigated the cardiac effects of an acute bout of exercise in close proximity to
      anthracycline infusion in humans. Aerobic exercise training is recommended throughout
      chemotherapy treatment, but there are no guidelines in place in terms of the timing of
      exercise in relation to receipt of chemotherapy infusions.

      4) Objectives

        1. To compare the acute effect of performing exercise (within 24 hours before the first
           infusion) compared to no exercise (no exercise for 72 hours prior to the first infusion)
           on markers of subclinical cardiotoxicity 24-48 hours after the first anthracycline
           infusion.

        2. To compare the chronic effect of performing exercise (within 24 hours before every
           infusion) compared to no exercise (no exercise for 72 hours prior to every infusion) on
           markers of cardiotoxicity 7 to 14 days after the final anthracycline infusion 5)
           Research Method This study will be a two-arm randomized control trial. Twenty-four women
           aged 18 or older newly diagnosed with stage I-IIIA breast cancer, and scheduled to
           receive neoadjuvant or adjuvant doxorubicin chemotherapy in cycles of 2-3 weeks will be
           recruited by oncologist referral and posters. Participants will be randomized to one of
           two conditions: i) an acute bout of exercise performed ≤24 hours prior to each cycle of
           anthracyclines and no exercise for 48 hours post; or ii) no exercise for 72 hours prior
           or 48 hours post each cycle of anthracyclines.

      6) Statistical Analysis The primary outcome will be global longitudinal strain measured by
      echocardiography. The secondary outcomes will be the NT-proBNP and cardiac troponin T cardiac
      biomarkers measured with an assay of blood taken via venous blood draw,
      echocardiography-derived left ventricular twist. The exploratory outcome measure will be
      treatment symptoms as reported by the Rotterdam Symptom Checklist. Cardiac outcome measures
      will be performed at the following time points: 1) Post diagnosis and prior to the first
      cycle of anthracyclines; 2) 24-48 hours after the first cycle; 3) at least one week after the
      last cycle of anthracyclines, but before subsequent chemotherapy treatments. The Rotterdam
      will be performed at baseline and within the last few days of each treatment cycle.

      Baseline characteristics of the two groups will be compared with independent t-tests.
      Descriptive statistics and frequencies will be calculated for all continuous and categorical
      variables. The acute effect will be determined by the difference between time points 1) and
      2). The chronic effect will be determined by the difference between time points 1) and 3).
      For each analysis, a linear mixed model with time as a fixed and repeated effect, group as a
      fixed effect, and a time by condition (2 x 2) interaction will be used. If the interaction
      effect is not statistically significant, the main effects of time and condition will be
      explored. An alpha of 0.05 will be used for all analyses.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 15, 2016</start_date>
  <completion_date type="Actual">May 25, 2016</completion_date>
  <primary_completion_date type="Actual">May 25, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global Longitudinal Strain</measure>
    <time_frame>24-48 hours after first doxorubicin and 7-14 days after completion of last doxorubicin cycle</time_frame>
    <description>Assessed with 2D speckle tracking echocardiography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NT-proBNP</measure>
    <time_frame>24-48 hours after first doxorubicin and 7-14 days after completion of last doxorubicin cycle</time_frame>
    <description>biomarker of cardiac injury</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Troponin T</measure>
    <time_frame>24-48 hours after first doxorubicin and 7-14 days after completion of last doxorubicin cycle</time_frame>
    <description>biomarker of cardiac injury</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV Twist</measure>
    <time_frame>24-48 hours after first doxorubicin and 7-14 days after completion of last doxorubicin cycle</time_frame>
    <description>Assessed with 2D speckle tracking echocardiography</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Patient-reported Symptoms</measure>
    <time_frame>&lt;1 week before the first doxorubicin, &lt;3 days before the 2nd, 3rd, and 4th doxorubicin, 7-14 days after completion of the last doxorubicin cycle</time_frame>
    <description>As assessed by standardized scores of physical and psychological distress by the Rotterdam Symptom Checklist</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>an acute bout of exercise performed ≤24 hours prior to each cycle of anthracyclines and no exercise for 48 hours post</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No exercise</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no exercise for 72 hours prior or 48 hours post each cycle of anthracyclines</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>exercise</intervention_name>
    <description>An acute bout of exercise performed 24 hours prior to every anthracycline infusion.</description>
    <arm_group_label>Exercise</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  newly diagnosed with stage I-IIIA breast cancer

          -  scheduled to receive neoadjuvant or adjuvant doxorubicin chemotherapy in cycles of 2-3
             weeks long

          -  receive their oncologist's approval to exercise

          -  be able to complete first time point of data collection prior to first chemotherapy
             cycle

          -  be able to understand and provide written informed consent in English

        Exclusion Criteria:

          -  concurrent participation in a structured exercise program or study

          -  have orthopedic limitations to exercise

          -  pre-existing cardiovascular disease

          -  uncontrolled hypertension (blood pressure ≥ 140/90 mmHg)

          -  uncontrolled diabetes

          -  respiratory disease

          -  current smoking status
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristin L Campbell, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of British Columbia Breast Cancer Research Exercise Gym</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>December 5, 2013</study_first_submitted>
  <study_first_submitted_qc>December 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2013</study_first_posted>
  <results_first_submitted>November 8, 2017</results_first_submitted>
  <results_first_submitted_qc>October 23, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 25, 2019</results_first_posted>
  <last_update_submitted>October 23, 2019</last_update_submitted>
  <last_update_submitted_qc>October 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Kristin Campbell</investigator_full_name>
    <investigator_title>Dr. Kristin Campbell</investigator_title>
  </responsible_party>
  <keyword>cardiotoxicity</keyword>
  <keyword>Chemotherapy, Adjuvant</keyword>
  <keyword>Breast Neoplasms</keyword>
  <keyword>Exercise</keyword>
  <keyword>Cardiotoxins</keyword>
  <keyword>Echocardiography</keyword>
  <keyword>Speckle tracking</keyword>
  <keyword>Biological Markers</keyword>
  <keyword>Electrocardiography</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Exercise</title>
          <description>an acute bout of exercise performed ≤24 hours prior to each cycle of anthracyclines and no exercise for 48 hours post
exercise: An acute bout of exercise performed 24 hours prior to every anthracycline infusion.</description>
        </group>
        <group group_id="P2">
          <title>Usual Care</title>
          <description>no exercise for 72 hours prior or 48 hours post each cycle of anthracyclines</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>One participant in the usual care group did not complete baseline assessment. One participant in usual care group completed baseline assessment before protocol violation (did not receive any of study drug) and was excluded. One participant in the exercise group withdrew immediately after the baseline assessment and did not start the intervention.</population>
      <group_list>
        <group group_id="B1">
          <title>Exercise</title>
          <description>an acute bout of exercise performed ≤24 hours prior to each cycle of anthracyclines and no exercise for 48 hours post exercise</description>
        </group>
        <group group_id="B2">
          <title>Usual Care</title>
          <description>no exercise for 72 hours prior or 48 hours post each cycle of anthracyclines</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" spread="9"/>
                    <measurement group_id="B2" value="50" spread="10"/>
                    <measurement group_id="B3" value="50" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.7" spread="11.7"/>
                    <measurement group_id="B2" value="72.2" spread="12.7"/>
                    <measurement group_id="B3" value="71.9" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin</title>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.0" spread="1.0"/>
                    <measurement group_id="B2" value="12.7" spread="1.1"/>
                    <measurement group_id="B3" value="12.8" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>6-month MVPA</title>
          <units>average weekly minutes</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="214" lower_limit="0" upper_limit="701"/>
                    <measurement group_id="B2" value="124" lower_limit="0" upper_limit="619"/>
                    <measurement group_id="B3" value="165" lower_limit="0" upper_limit="701"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LVEF</title>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" spread="4"/>
                    <measurement group_id="B2" value="58" spread="3"/>
                    <measurement group_id="B3" value="58" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cardiac output</title>
          <units>L/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.2" spread="0.6"/>
                    <measurement group_id="B2" value="3.0" spread="0.5"/>
                    <measurement group_id="B3" value="3.1" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Resting HR</title>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69" spread="11"/>
                    <measurement group_id="B2" value="69" spread="12"/>
                    <measurement group_id="B3" value="69" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systemic vascular resistance</title>
          <units>dynes·sec·cm−5</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1933" spread="445"/>
                    <measurement group_id="B2" value="2074" spread="514"/>
                    <measurement group_id="B3" value="1998" spread="472"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>E/A ratio</title>
          <units>no units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.20" spread="0.37"/>
                    <measurement group_id="B2" value="1.27" spread="0.32"/>
                    <measurement group_id="B3" value="1.23" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean arterial pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75" spread="10"/>
                    <measurement group_id="B2" value="76" spread="11"/>
                    <measurement group_id="B3" value="76" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.0" spread="4.8"/>
                    <measurement group_id="B2" value="26.7" spread="5.1"/>
                    <measurement group_id="B3" value="25.8" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Global Longitudinal Strain</title>
        <description>Assessed with 2D speckle tracking echocardiography</description>
        <time_frame>24-48 hours after first doxorubicin and 7-14 days after completion of last doxorubicin cycle</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exercise</title>
            <description>an acute bout of exercise performed ≤24 hours prior to each cycle of anthracyclines and no exercise for 48 hours post exercise</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>no exercise for 72 hours prior or 48 hours post each cycle of anthracyclines</description>
          </group>
        </group_list>
        <measure>
          <title>Global Longitudinal Strain</title>
          <description>Assessed with 2D speckle tracking echocardiography</description>
          <units>% deformation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.2" spread="1.9"/>
                    <measurement group_id="O2" value="-19.6" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24-48 h post first doxorubicin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4" spread="1.8"/>
                    <measurement group_id="O2" value="-21.5" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7-14 days post last doxorubicin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.7" spread="1.4"/>
                    <measurement group_id="O2" value="-20.3" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>NT-proBNP</title>
        <description>biomarker of cardiac injury</description>
        <time_frame>24-48 hours after first doxorubicin and 7-14 days after completion of last doxorubicin cycle</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exercise</title>
            <description>an acute bout of exercise performed ≤24 hours prior to each cycle of anthracyclines and no exercise for 48 hours post exercise</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>no exercise for 72 hours prior or 48 hours post each cycle of anthracyclines</description>
          </group>
        </group_list>
        <measure>
          <title>NT-proBNP</title>
          <description>biomarker of cardiac injury</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52" spread="30"/>
                    <measurement group_id="O2" value="59" spread="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24-48 h post first doxorubicin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="214" spread="77"/>
                    <measurement group_id="O2" value="323" spread="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7-14 days post last doxorubicin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106" spread="78"/>
                    <measurement group_id="O2" value="77" spread="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Troponin T</title>
        <description>biomarker of cardiac injury</description>
        <time_frame>24-48 hours after first doxorubicin and 7-14 days after completion of last doxorubicin cycle</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exercise</title>
            <description>an acute bout of exercise performed ≤24 hours prior to each cycle of anthracyclines and no exercise for 48 hours post exercise</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>no exercise for 72 hours prior or 48 hours post each cycle of anthracyclines</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Troponin T</title>
          <description>biomarker of cardiac injury</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="2.1"/>
                    <measurement group_id="O2" value="1.5" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24-48 h post first doxorubicin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="3.2"/>
                    <measurement group_id="O2" value="1.9" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7-14 days post last doxorubicin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6" spread="11.2"/>
                    <measurement group_id="O2" value="11.6" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LV Twist</title>
        <description>Assessed with 2D speckle tracking echocardiography</description>
        <time_frame>24-48 hours after first doxorubicin and 7-14 days after completion of last doxorubicin cycle</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exercise</title>
            <description>an acute bout of exercise performed ≤24 hours prior to each cycle of anthracyclines and no exercise for 48 hours post exercise</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>no exercise for 72 hours prior or 48 hours post each cycle of anthracyclines</description>
          </group>
        </group_list>
        <measure>
          <title>LV Twist</title>
          <description>Assessed with 2D speckle tracking echocardiography</description>
          <units>degrees</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4" spread="7.6"/>
                    <measurement group_id="O2" value="16.4" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24-48 h post first doxorubicin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.3" spread="8.5"/>
                    <measurement group_id="O2" value="22.4" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7-14 days post last doxorubicin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7" spread="6.5"/>
                    <measurement group_id="O2" value="15.6" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Patient-reported Symptoms</title>
        <description>As assessed by standardized scores of physical and psychological distress by the Rotterdam Symptom Checklist</description>
        <time_frame>&lt;1 week before the first doxorubicin, &lt;3 days before the 2nd, 3rd, and 4th doxorubicin, 7-14 days after completion of the last doxorubicin cycle</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During intervention period which lasted from shortly prior to the first doxorubicin treatment to 7-14 days after the last doxorubicin treatment.</time_frame>
      <desc>Serious adverse events related to the study intervention.</desc>
      <group_list>
        <group group_id="E1">
          <title>Exercise</title>
          <description>an acute bout of exercise performed ≤24 hours prior to each cycle of anthracyclines and no exercise for 48 hours post exercise</description>
        </group>
        <group group_id="E2">
          <title>Usual Care</title>
          <description>no exercise for 72 hours prior or 48 hours post each cycle of anthracyclines</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Amy Kirkham, Postdoctoral Research Fellow</name_or_title>
      <organization>University of Alberta</organization>
      <phone>7804926874</phone>
      <email>amy.kirkham@ualberta.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

